1. Cellular anti-GP120 cytolytic reactivities in HIV-1 seropositive individuals.
- Author
-
Weinhold KJ, Lyerly HK, Matthews TJ, Tyler DS, Ahearne PM, Stine KC, Langlois AJ, Durack DT, and Bolognesi DP
- Subjects
- Antibodies, Monoclonal analysis, HIV Antibodies, HIV Envelope Protein gp120, Humans, Interleukin-2 pharmacokinetics, Killer Cells, Natural drug effects, Phenotype, Recombinant Proteins pharmacokinetics, Retroviridae Proteins pharmacokinetics, Stimulation, Chemical, T-Lymphocytes immunology, T-Lymphocytes metabolism, Viral Envelope Proteins metabolism, Viral Envelope Proteins pharmacokinetics, Antibodies, Viral analysis, Antibody-Dependent Cell Cytotoxicity drug effects, Deltaretrovirus immunology, HIV Seropositivity immunology, Retroviridae Proteins immunology, Viral Envelope Proteins immunology
- Abstract
Forty-one patients seropositive for human immunodeficiency virus type 1 (HIV-1) were assessed for cell-mediated cytotoxicity (CMC) against autologous target cells bearing the major envelope glycoprotein of HIV-1, gp120. Effector lymphocytes from over 85% of seropositive patients showed CMC specific for gp120-coated targets, whereas seronegative individuals had no detectable CMC. As a group, symptomless individuals had the highest levels of CMC; patients with AIDS-related complex and AIDS showed progressively diminished reactivity. The gp120-specific CMC was mediated by a population of non-T-cell effectors phenotypically resembling NK/K cells. Cytolysis was not restricted by major histocompatibility complex determinants, as shown by killing of heterologous gp120-adsorbed targets and of HIV-1-infected cell-lines. Gp120-specific CMC was highly augmented in the presence of interleukin 2, so it may be possible to develop therapeutic strategies aimed at destruction of virus-producing cell reservoirs in infected individuals through stimulation of HIV-specific host CMC.
- Published
- 1988
- Full Text
- View/download PDF